Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.85M | -45.43M | -42.98M | -40.86M | -40.23M |
| Total Depreciation and Amortization | 530.00K | 538.00K | 545.00K | 551.00K | 544.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.42M | 4.16M | 3.82M | 3.37M | 3.66M |
| Change in Net Operating Assets | 1.16M | 3.04M | 4.05M | 4.87M | 6.06M |
| Cash from Operations | -42.75M | -37.69M | -34.57M | -32.07M | -29.97M |
| Capital Expenditure | 0.00 | -80.00K | -88.00K | -403.00K | -654.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.49M | 13.81M | 22.87M | 36.44M | 34.16M |
| Cash from Investing | -5.49M | 13.73M | 22.78M | 36.03M | 33.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 53.68M | 53.78M | 9.59M | 2.17M | 107.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 53.68M | 53.78M | 9.59M | 2.17M | 107.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.44M | 29.82M | -2.20M | 6.13M | 3.64M |